Skip to content

Morphine vs Sufentanil PCA: Same Same or Different?

Sufentanil Sublingual Tablet System vs Intravenous Patient-Controlled Analgesia With Morphine: Postoperative Pain Control and Its Impact in Quality of Recovery

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05259098
Enrollment
54
Registered
2022-02-28
Start date
2019-10-01
Completion date
2020-10-31
Last updated
2022-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesia, Chronic Pain, Patient Satisfaction, Post Operative Pain

Brief summary

Patient-controlled intravenous analgesia (PCA) has already proven its quality. However, with new strategies starting to emerge and the current concept of opioid sparing, it is a goal to find the optimal PCA strategy capable of improve patient satisfaction and, at the same time, individualize opioid dose. In a prospected randomized study, it was compared the use of Sufentanil Sublingual PCA System with intravenous PCA Morphine in terms of postoperative pain control satisfaction, total dose of opioid required, adverse effects, impact on the quality of postoperative recovery and the incidence of postoperative chronic pain.

Detailed description

In a prospected randomized study, it was compared the use of Sufentanil Sublingual PCA System (15mcg per tablet, 20 minutes lockout) with intravenous PCA Morphine based on 1mg morphine on-demand 10 minutes lockout and a baseline perfusion of 1mg/hour. 45 patients capable of comply a PCA regime submitted to total knee arthroplasty, total hip arthroplasty and abdominal hysterectomy were enrolled in the study. During the first 48 hours, it was accessed daily pain scores, PCA use, need for rescue therapy, adverse effects, global satisfaction as well as postoperative quality recovery. Brief Pain Inventory was performed before surgery and 4 months later.

Interventions

DRUGSufentanil Sublingual Tablet System

Sufentanil Sublingual Tablet System is a sublingual opioid patient controlled analgesia system. It was used for postoperative analgesia after surgery associated with moderate to severe pain.

DRUGIntravenous Patient-Controlled Analgesia with morfine

Intravenous Patient-Controlled Analgesia with morfine. It was used for postoperative analgesia after surgery associated with moderate to severe pain.

Sponsors

Hospital Central do Funchal
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Informed consent signed; * Age superior to 18 years; * Physical status according to the American Society of Anesthesiology (ASA) 1-3; * Scheduled gynecological surgery: abdominal hysterectomy * Scheduled orthopedic surgery: total knee arthroplasty or total hip arthroplasty.

Exclusion criteria

* Patient refusal to participate in the study; * Age \<18 years or legal dependence; * Neurological or psychiatric pathology or altered state of consciousness that does not allow for the Patient Controlled Analgesia strategy; * Documented drinking habits and/or consumption of illicit drugs; * Patients tolerant to opioid therapy (use of \>15 mg oral morphine or its equivalent per day for the last 3 months); * Documented obstructive Sleep Apnea Syndrome (OSAS); * Patients on long-term oxygen therapy; * Intraoperative use of intrathecal morphine; * Use of anesthetic techniques in order to provide postoperative analgesia (eg, epidural catheter; peripheral nerve block; infiltration of the surgical wound with local anesthetic).

Design outcomes

Primary

MeasureTime frameDescription
Postoperative pain controlEvaluation at 24 hours and 48 hours after surgeryComparison between patient controlled analgesia with IV morphine and sublingual sufentanil in Numeric Rating Scale

Secondary

MeasureTime frameDescription
Adverse effects associated with analgesiaEvaluation at 24 hours and 48 hours after surgeryEvaluation of adverse effects of the PCA systems: sedation using the Richamond Agitation Sedation Scale (RASS); hypoxemia without oxygen supplementation: mild to moderate (SpO2 90-93%) or severe (SpO2\<90%); hypotension; nausea or vomiting; dyspepsia; itching
Total daily dose of opioidEvaluation at 24 hours and 48 hours after surgeryEvaluation of total daily dose of each drug
Patients satisfaction with analgesiaEvaluation at 24 hours and 48 hours after surgeryEvaluation of patient satisfaction using a qualitative scale: Poor; Average; Good; Excellent
Impact of the treatment on the quality of postoperative recoveryEvaluation at 24 hours after surgeryEvaluation of recovery with application of validated quality of recovery score (QoR-15) questionnaire
Incidence of postoperative chronic pain4 months after surgeyAssessment to persistent postoperative pain by completing the Brief Pain Inventory

Countries

Portugal

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026